Elizabeth T Rogawski1,2, James A Platts-Mills2, E Ross Colgate3, Rashidul Haque4, K Zaman4, William A Petri2, Beth D Kirkpatrick3. 1. Department of Public Health Sciences, University of Virginia, Charlottesville. 2. Division of Infectious Diseases and International Health, University of Virginia, Charlottesville. 3. Department of Medicine and Vaccine Testing Center, University of Vermont College of Medicine, Burlington. 4. International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
Abstract
Background: The low efficacy of rotavirus vaccines in clinical trials performed in low-resource settings may be partially explained by acquired immunity from natural exposure, especially in settings with high disease incidence. Methods: In a clinical trial of monovalent rotavirus vaccine in Bangladesh, we compared the original per-protocol efficacy estimate to efficacy derived from a recurrent events survival model in which children were considered naturally exposed and potentially immune after their first rotavirus diarrhea (RVD) episode. We then simulated trial cohorts to estimate the expected impact of prior exposure on efficacy estimates for varying rotavirus incidence rates and vaccine efficacies. Results: Accounting for natural immunity increased the per-protocol vaccine efficacy estimate against severe RVD from 63.1% (95% confidence interval [CI], 33.0%-79.7%) to 70.2% (95% CI, 44.5%-84.0%) in the postvaccination period, and original year 2 efficacy was underestimated by 14%. The simulations demonstrated that this expected impact increases linearly with RVD incidence, will be greatest for vaccine efficacies near 50%, and can reach 20% in settings with high incidence and low efficacy. Conclusions: High rotavirus incidence leads to predictably lower vaccine efficacy estimates due to the acquisition of natural immunity in unvaccinated children, and this phenomenon should be considered when comparing efficacy estimates across settings. Clinical Trials Registration: NCT01375647.
RCT Entities:
Background: The low efficacy of rotavirus vaccines in clinical trials performed in low-resource settings may be partially explained by acquired immunity from natural exposure, especially in settings with high disease incidence. Methods: In a clinical trial of monovalent rotavirus vaccine in Bangladesh, we compared the original per-protocol efficacy estimate to efficacy derived from a recurrent events survival model in which children were considered naturally exposed and potentially immune after their first rotavirus diarrhea (RVD) episode. We then simulated trial cohorts to estimate the expected impact of prior exposure on efficacy estimates for varying rotavirus incidence rates and vaccine efficacies. Results: Accounting for natural immunity increased the per-protocol vaccine efficacy estimate against severe RVD from 63.1% (95% confidence interval [CI], 33.0%-79.7%) to 70.2% (95% CI, 44.5%-84.0%) in the postvaccination period, and original year 2 efficacy was underestimated by 14%. The simulations demonstrated that this expected impact increases linearly with RVD incidence, will be greatest for vaccine efficacies near 50%, and can reach 20% in settings with high incidence and low efficacy. Conclusions: High rotavirus incidence leads to predictably lower vaccine efficacy estimates due to the acquisition of natural immunity in unvaccinated children, and this phenomenon should be considered when comparing efficacy estimates across settings. Clinical Trials Registration: NCT01375647.
Authors: S A Madhi; M Kirsten; C Louw; P Bos; S Aspinall; A Bouckenooghe; K M Neuzil; A D Steele Journal: Vaccine Date: 2012-04-27 Impact factor: 3.641
Authors: Samba O Sow; Milagritos Tapia; Fadima C Haidara; Max Ciarlet; Fatoumata Diallo; Mamoudou Kodio; Moussa Doumbia; Rokiatou D Dembélé; Oumou Traoré; Uma U Onwuchekwa; Kristen D C Lewis; John C Victor; A Duncan Steele; Kathleen M Neuzil; Karen L Kotloff; Myron M Levine Journal: Vaccine Date: 2012-04-27 Impact factor: 3.641
Authors: Beth D Kirkpatrick; E Ross Colgate; Josyf C Mychaleckyj; Rashidul Haque; Dorothy M Dickson; Marya P Carmolli; Uma Nayak; Mami Taniuchi; Caitlin Naylor; Firdausi Qadri; Jennie Z Ma; Masud Alam; Mary Claire Walsh; Sean A Diehl; William A Petri Journal: Am J Trop Med Hyg Date: 2015-02-23 Impact factor: 2.345
Authors: F R Velázquez; D O Matson; J J Calva; L Guerrero; A L Morrow; S Carter-Campbell; R I Glass; M K Estes; L K Pickering; G M Ruiz-Palacios Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: Ally Olotu; Gregory Fegan; Juliana Wambua; George Nyangweso; Amanda Leach; Marc Lievens; David C Kaslow; Patricia Njuguna; Kevin Marsh; Philip Bejon Journal: N Engl J Med Date: 2016-06-30 Impact factor: 91.245
Authors: K Zaman; Jessica A Fleming; John C Victor; Mohammad Yunus; Tajul Islam A Bari; Tasnim Azim; Mustafizur Rahman; Syed Mohammad Niaz Mowla; William J Bellini; Monica McNeal; Joseph P Icenogle; Ben Lopman; Umesh Parashar; Margaret M Cortese; A Duncan Steele; Kathleen M Neuzil Journal: J Infect Dis Date: 2016-01-27 Impact factor: 5.226
Authors: Virginia E Pitzer; Aisleen Bennett; Naor Bar-Zeev; Khuzwayo C Jere; Benjamin A Lopman; Joseph A Lewnard; Umesh D Parashar; Nigel A Cunliffe Journal: Sci Transl Med Date: 2019-08-14 Impact factor: 17.956
Authors: Michael Haber; Jacqueline E Tate; Benjamin A Lopman; Wenrui Qi; Kylie E C Ainslie; Umesh D Parashar Journal: Hum Vaccin Immunother Date: 2021-10-06 Impact factor: 4.526
Authors: Alicia N M Kraay; Edward L Ionides; Gwenyth O Lee; William F Cevallos Trujillo; Joseph N S Eisenberg Journal: Int J Epidemiol Date: 2020-10-01 Impact factor: 7.196
Authors: Joseph A Lewnard; Benjamin A Lopman; Umesh D Parashar; Aisleen Bennett; Naor Bar-Zeev; Nigel A Cunliffe; Prasanna Samuel; M Lourdes Guerrero; Guillermo Ruiz-Palacios; Gagandeep Kang; Virginia E Pitzer Journal: PLoS Comput Biol Date: 2019-07-26 Impact factor: 4.475